Detection Of The Frequency Of Per- Type STUDY

Detection the frequency of PER-1 type extended-spectrum ß-lactamase-producing Acinetobacter baumannii clinical isolates in Turkey: a multicenter study

b-Lactamases are an important resistance mechanism in Acinetobacter baumannii. Pseudomonas extended-resistance (PER-1) type b-lactamase-producing strains have been reported from various geographic locations; however, PER-1 type b-lactamases from Turkish hospitals have not been investigated extensively. The aim of this study was to determine the prevalence of PER-1 type b-lactamases in A. baumannii isolates in various regions of Turkey. Materials and methods: A total of 763 clinical A. baumannii isolates were collected from 9 university hospitals and 2 state hospitals between 2008 and 2011. Molecular amplification of the OXA-51 gene from the A. baumannii genome was performed in order to verify identification of the species. Real-time polymerase chain reaction was used to detect blaPER-1 genes. Results: PER-1 was detected in 24.6% of the isolates. The annual frequencies of the PER-1 enzyme were detected as 52.2%, 35.9%, and 8.3% in 2008, 2009, and 2010, respectively. PER-1 prevalence decreased gradually over time. The differences observed in PER-1 prevalence among the regions of Turkey were statistically significant (chi-square test; P < 0.001). Conclusion: These data demonstrate that the frequency of detection of PER-1 type b-lactamases in A. baumannii species has decreased in Turkey. However, the increased carbapenem resistance, together with multidrug resistance, has created a worrisome situation regarding this pathogen.

Anahtar Kelimeler:

Acinetobacter baumannii, b-lactamases, PER-1

Detection the frequency of PER-1 type extended-spectrum ß-lactamase-producing Acinetobacter baumannii clinical isolates in Turkey: a multicenter study

Keywords:

Acinetobacter baumannii, b-lactamases, PER-1,

PDF

___

Bergogne-Berezin E. Resistance of Acinetobacter spp. to antimicrobials: overview of clinical resistance patterns and therapeutic problems. In: Bergogne-Berezin E, Joly-Guillou ML, Towner KJ, editors. Acinetobacter: Microbiology, Epidemiology, Infections, Management. Boca Raton, FL, USA: CRC Press; 1996. pp. 133–183.
Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358: 1271–1281.
Towner KJ. Molecular basis of antibiotic resistance in Acinetobacter spp. In: Gerisher U, editor. Acinetobacter Molecular Biology. Norfolk, UK: Caister Academic Press; 2008. pp. 322–343.
Brown S, Young HK, Amyes SGB. Characterisation of OXA-51, a novel class D cephalosporinase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin Microbiol Infect 2005; 11: 15–23.
Nordman P, Ronco E, Naas T, Duport C, Michel Briand Y, Labia R. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 962–969.
Vahaboglu H, Ozturk R, Aygun G, Coskunkan F, Yaman A, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Oktun M. Widespread of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41: 2265–2269.
Kolayli F, Gacar G, Karadenizli A, Sanic A, Vahaboglu H. PER- 1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp. FEMS Microbiol Lett 2005; 249: 241–245.
Erac B, Gulay Z. Molecular epidemiology of PER-1 extended spectrum β-lactamase among gram-negative bacteria isolated at a tertiary care hospital. Folia Microbiol 2007; 52: 535–541.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 17th Infor- mational Supplement. Wayne, PA, USA: Clinical and Labora- tory Standards Institute; 2007.
Bogner PN, Killeen AA. Extraction of nucleic acids. In: Cole- man WB, Tsongalis GJ, editors. Molecular Diagnostics: For the Clinical Laboratorian. New York, NY, USA: Humana Press; 2007. pp. 25–30.
Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical iso- lates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 2008; 52: 3837–3843.
Turner PJ, Greenhalgh JM; MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997–2000. Clin Microbiol Infect 2003; 9: 563–567.
Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N, Cevik MA. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008; 12: 16–21.
Karageorgopoulos DE, Falagas ME. Current control and treat- ment of multidrug-resistant Acinetobacter baumannii infec- tions. Lancet Infect Dis 2008; 8: 751–762.
Kean SJ. Doripenem: a review of its use in the treatment of bac- terial infections. Drugs 2008; 68: 2021–2057.
Pagani L, Mantengoli E, Migliavacca R, Nucleo E, Pollini S, Spalla M, Daturi R, Romero E, Rossolini GM. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase in northern Italy. J Clin Microbiol 2004; 42: 2523–2529.
De Champs C, Poirel L, Bonnet R, Sirot D, Chanal C, Sirot J, Nordmann P. Prospective survey of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002; 46: 3031–3034.
Naas T, Bogaerts P, Bauraing C, Degheldre Y, Glupczynski Y, Nordmann P. Emergence of PER and VEB extended-spectrum beta-lactamases in Acinetobacter baumannii in Belgium. J Antimicrob Chemother 2006; 58: 178–182.
Miro E, Mirelis B, Navarro F, Rivera A, Mesa RJ, Roig MC, Gomez L, Coll P. Surveillance of extended-spectrum beta- lactamases from clinical samples and faecal carriers in Barcelona, Spain. J Antimicrob Chemother 2005; 56: 1152– 1155.
Empel J, Filczak K, Mrowka A, Hryniewicz W, Livermore DM, Gniadkowski M. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol 2007; 45: 2829–2834.
Naas T, Nordmann P, Heidt A. Intercountry transfer of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter baumannii from Romania. Int J Antimicrob Agents 2007; 29: 226–228.
Yamano Y, Nishikawa T, Fujimura T, Yutsudou T, Tsuji M, Miwa H. Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem. J Antibiot (Tokyo) 2006; 59: 791–796.
Lee S, Park YJ, Kim M, Lee HK, Han K, Kang CS, Kang MW. Prevalence of Ambler class A and D beta-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimi- crob Chemother 2005; 56: 122–127.
Jeong SH, Bae IK, Kwon SB, Lee K, Yong D, Woo GJ, Lee JH, Jung HI, Jang SJ, Sung KH et al. Investigation of a nosocomial outbreak of Acinetobacter baumannii producing PER-1 extended spectrum beta-lactamase in an intensive care unit. J Hosp Infect 2005; 59: 242–248.
Eraç B, Hoşgör-Limoncu M, Ermertcan Ş, Taşlı H, Aydemir Ş. Prevalence of blaPER-1 and integrons in ceftazidime-resistant Gram-negative bacteria at a university hospital in Turkey. Jpn J Infect Dis 2013; 66: 146–148.
Vahaboglu H, Coskunkan F, Tansel O, Ozturk R, Sahin N, Koksal I, Kocazeybek B, Tatman-Otkun M, Leblebicioglu H, Ozinel MA et al. Clinical importance of extended-spectrum ß-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J Med Microb 2001; 50: 642– 645.